Research Nester released a report titled “Non-Small Cell Lung Cancer Treatment Market: Global Demand Analysis & Opportunity Outlook 2029″ which delivers detailed overview of the global non-small cell lung cancer treatment market in terms of market segmentation by treatment type, end-user, and region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The non-small cell lung cancer treatment market is projected to grow with a high CAGR during the forecast period, i.e., 2021-2029 on account of the increasing prevalence of non-small cell lung cancer and rising awareness about the disease. According to World Health Organization, in 2020, there were around 2.21 million new cases and 1.80 million deaths from lung cancer globally.
The market is segmented by treatment type into surgery, radiofrequency ablation, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. Among these segments, the targeted therapy segment is anticipated to hold the largest share by the end of 2021 in the non-small cell lung cancer treatment market as a result of the higher rates of adoption of targeted therapy than other available treatments. It is also gaining worldwide recognition for its usage as an adjuvant therapy with chemotherapy.
Request Sample For More Information@ https://www.researchnester.com/sample-request-3024
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which, the non-small cell lung cancer treatment market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period. Currently, the market in North America holds the largest share. This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative non-small cell lung cancer treatment procedures.
Increasing Prevalence of Non-Small Cell Lung Cancer and Rising Awareness about the Disease to Drive Market Growth
According to the American Cancer Society, it is estimated that in 2021, there would be about 235, 760 new cases and about 131,880 deaths from lung cancer in U.S.
Non-small cell lung cancer is the most commonly occurring forms of lung cancer. The increasing prevalence of non-small lung cancer has led to the increase in demand for non-small lung cancer therapeutics. Additionally, the rising awareness about non-small cell lung cancer in recent years is also expected to boost the market growth in upcoming years.
However, the limited treatment options for non-small lung cancer and lack of awareness about the disease in lower economic regions are some of the factors that are estimated to restrain market growth in the near future.
Grab PDF Sample For More Information@ https://www.researchnester.com/sample-request-3024
This report also provides the existing competitive scenario of some of the key players of the global non-small cell lung cancer treatment market which includes company profiling of Genentech, Inc., Celgene Corporation (Bristol Myers Squibb), AstraZeneca plc (LON: AZN), Elli Lilly & Company (NYSE: LLY), Pfizer Inc. (NYSE: PFE), Sanofi (EPA: SAN), Astellas Pharma Inc. (TYO), Novartis AG (SWX: NOVN), Takeda Oncology, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global non-small cell lung cancer treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
About Research Nester
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]